What is TIL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TIL?

P/E (TTM) is n/a and 52-week range is $5.67 to $21.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TIL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TIL?

The company profile lists net income (TTM) near $-30M, EPS (TTM) near $-4.47 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Instil Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Dallas, Texas, US, 6.8M shares outstanding, ISIN US45783C2008 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Instil Bio Inc

$TIL

Health Care · Biotechnology

IR Run Scenarios

$6.74

+2.74%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 17 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

Employees

Website

instilbio.com/

IPO

2021-03-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)